PLX Stock Gets Reduced EPS Forecast from HC Wainwright

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at HC Wainwright reduced their Q4 2026 earnings estimates for shares of Protalix BioTherapeutics in a research report issued on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.04) per share for the quarter, down from their prior estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2027 earnings at $0.02 EPS, Q3 2027 earnings at $0.13 EPS and FY2027 earnings at $0.19 EPS.

Protalix BioTherapeutics Price Performance

NYSE PLX opened at $2.96 on Friday. The business has a fifty day moving average price of $2.68 and a two-hundred day moving average price of $2.44. The stock has a market capitalization of $238.49 million, a PE ratio of -22.77 and a beta of 0.01. Protalix BioTherapeutics has a fifty-two week low of $1.65 and a fifty-two week high of $3.19.

Institutional Trading of Protalix BioTherapeutics

Several large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Protalix BioTherapeutics in the second quarter valued at about $9,429,000. Dimensional Fund Advisors LP lifted its holdings in shares of Protalix BioTherapeutics by 932.7% in the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after acquiring an additional 268,099 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Protalix BioTherapeutics in the second quarter worth about $543,000. Russell Investments Group Ltd. boosted its stake in shares of Protalix BioTherapeutics by 903.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 248,557 shares of the company’s stock valued at $686,000 after purchasing an additional 223,792 shares in the last quarter. Finally, Deutsche Bank AG acquired a new stake in shares of Protalix BioTherapeutics in the 2nd quarter valued at approximately $181,000. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.